applepharmaceutical@gmail.com
Lopimune

PRODUCT DETAILS

Trade name : Lopimune
Active ingredient : Lopinavir & ritonavir
Strength availability : 200mg & 50mg
Manufactured by : Cipla
Package : 60 tablets in a container

for MORE INFORMATION !!!

Lopimune is a fixed dose combinational treatment which is also used with other HIV drugs. Lopimune tablets involves in anti-retroviral agent which includes Lopinavir & ritonavir as an active substances. Both are classified pharmacologically as protease inhibitors. Lopimune tablets are not a curable disease, Lopimune is a prescription drugs only under the guidance of physician.

INDICATION

Lopimune is primarily used to treat in patients suffering from HIV-1 infection by combining with other anti-retroviral drugs.

PHARMACOLOGY

MECHANISM OF ACTION :
Lopinavir belongs to an inhibitor of the HIV-1 protease, inhibits cleavage of the Gag-Pol polyprotein, resulting in the formation of immature, non-infectious viral particles. Ritonavir prohibits the CYP3A-mediated metabolism of lopinavir, hence providing increased plasma levels of lopinavir.

DOSAGE

In adults, the usual dose of Lopimune is 400mg/100mg that is 2 tablets of Lopimune It should be administered orally as two times a day. The dose prescribed as 800/200mg (given as 4 tablets of 200/50mg) once daily in patients with < 3 lopinavir resistance associated substitions Lopimune is not recommended once daily in combination with anticonvulsant drugs, Combination of Lopimune with Efavirenz, nevirapine or nelfinavir once daily is not recommended Thereby dose increased for all patients is 500/125mg of Lopimune tablets in combination with Efavirenz, nevirapine or nelfinavir is given twice daily as two tablet of 200/50mg and one tablet of 100/25mg. Pediatric patients: Lopimune should not administrated once daily in patients < 18 years of age the tablet Based on BSA or Weight the Lopimune dose is calculated.
6 months to 18 years :
The patients administrated dose of 15 -25 kg or BSA < 0.9 m2 – lopinavir 200mg & Ritonavir 50mg twice a day orally >25 – 35 kg or BSA 0.9 to < 1.4 m2 – lopinavir 300mg & Ritonavir 75 mg twice daily orally. The patients administrated dose of greater than 35kg or BSA at least 1.4m2 – lopinavir 400mg & Ritonavir 100mg twice daily orally.
Concomitant Efavirenz, nelfinavir or nevirapine :
The dose administrated 15 -20kg or BSA 0.6 to < 0.8m2 – Lopinavir 200mg & Ritonavir 50mg orally. >20 – 30kg or BSA 0.8 <1.2m2 – lopinavir 300mg – Ritonavir 75mg orally twice a day. > 30 – 45 kg or BSA 1.2 to <1.7m2 – lopinavir 400mg – Ritonavir 100mg orally twice a day > 45kg or BSA at least 1.7m2: - Lopinavir 500mg & Ritonavir 125mg twice a day orally. Lopimune tablets should be administered with food or without food. Lopimune tablets should not be chewed, crushed or broke

PHARMACOKINETIC

Absorption: The time to peak plasma concentration of Lopinavir occurs at 4 hours approximately. While taking Lopimune with or without food no alteration of pharmacokinetic effect occurs.
Distribution: Lopinavir & Ritonavir are heavily bound to human plasma protein with the range of 98 to 99%.
Metabolism :
Lopinavir Mainly metabolized in hepatically, by using CYP3A isoenzymes. Ritonavir in circulation is produce as an unchanged form,. The primary metabolite of Ritonavir is Isopropylthiazole oxidation metabolite which is present as low level attaining anti-retroviral activity. CYP3A & CYP2D6 isoenzymes are main cytochrome enzyme required for metabolism of ritonavir.
Excretion: The Ritonavir half life period is 3 to 5 hours and Ritonavir metabolite should be eliminated through feces & urine. The Lopinavir half life period of is 12 hours after dosing with range of 5 to 6 hours The unchanged form of Lopinavir is encountered with the range of via urine 2.2% & feces 19.8%.

WARNING & PRECAUTION

QT prolongation: Stop the therapy.
Immune reconstitution syndrome: Discontinue the Lopimune treatment
Fat redistribution: Reaccumulation of fat occur which may results as obesity. In severe condition, discontinue the therapy. Diabetes mellitus: Patients blood glucose level should be maintained by checking the levels frequently. Take alcohol & propylene glycol from all the drugs should be given to infants for reducing thwe toxicity associated to the components.
Pancreatitis: Elevation of triglyceride levels may leads to cause pancreatitis. Pancreatitis is the major risk factor during the Lopimune treatment. Lipase and amylase value should be monitored periodically.
Liver toxicity: Due to elevation of AST, ALT & bilirubin, leads to cause liver injury this may concluds as liver damage or failure. Monitor liver function test periodically during or after completion of treatment. Drug interaction-CYP3A enzyme prohibition, causes increased plasma concentration of concurrent used drugs. Avoid the concomitant use. Toxicity occurs to neonates, potential risk may occur while using Lopimune in neonates.

DRUG INTERACTION

Interaction of Lopimune with calcium channel blocker leads to cause elevating the effect of concentration of these drugs. Interaction of Lopimune is an inhibitor of CYP3A, may uplift the plasma concentration of agents that ate formerly metabolized by CYP3A. While Lopimune is a CYP3A substrate, when Lopimune is co administered with CYP3A inducers causes depletion of Lopinavir plasma concentration and leads to loss of effectiveness. Lopimune interaction with NNRTI like efavirenz or nevirapine causes decreasing the effect of concentration of Lopinavir. Lopimune interaction with tenofovir, causes increasing effect of concentration of tenofovir. Combination of Lopimune tablets with lipid lowering drugs or Immuno suppressants leads to cause increasing concentration of these drugs Concomitant use with abacavir, leads to decreasing the effect of concentration of abacavir. Interaction of Lopimune with anti-gout or anti-mycobacterials causes increasing effect of concentration of these drugs.

CONTRAINDICATION

Drugs that are largely vulnerable on CYP3A for clearance & for which increased plasma concentration are related with severe life threatening conditions during concurrent use of Lopimune is contraindicated. Lopimune is contraindicated by using with strong CYP3A inducers, causes decreasing Lopinavir plasma concentration.

MISSED DOSE

If missed dose occurs, patient should be following the instructions provided by medical adviser. Missed dose of Lopimune should be avoided.Regular dosing schedule should be maintained.

STORAGE

Lopimune drug should be stored at 20℃ to 25℃. Protect the drug from heat, moisture & light.

SIDE EFFECTS

Common side effects :
GI effects: abdominal pain, nausea, vomiting, diarrhea, anorexia Common side effects Hyperaesthesia, pharyngitis, rash, pruritus, sweating, vasodilatation, wt loss, Asthenia , taste disorder, headache, numbness or tingling around the mouth or extremities, anxiety, insomnia, fever, dizziness, malaise, Allergic reactions : urticaria, bronchospasm, angioedema, mild skin eruptions, immune reconstitution syndrome, lipodystrophy, osteonecrosis, Metabolic abnormalities: hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia, hyperlactataemia. Reduced levels of Hb, K, free and total thyroxine; increased eosinophil, liver enzymes, amylase and uric acid; reduced or increased WBC and neutrophil counts.

MAJOR SIDE EFFECTS

Pancreatitis, hepatic dysfunction, Stevens-Johnson syndrome. Rarely, anaphyla Post marketing: Fat redistribution Brady arrhythmias Toxic epidermal necrolysis, Stevens Johnson’s syndrome Erythema multiforme

We'd Like to Hear From You!

PRESCRIPTION POLICY

1. myapplepharma.com, a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. myapplepharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the myapplepharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. myapplepharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from myapplepharma.com.
6. At myapplepharma.com, a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether to accept this product or any other medicine. Only a health care provider is knowledge and training to decide that a medicine suitable for a specific patient. This information does not support any drug as safe, are effective or approved for the treatment of any patient or health condition. It's simple a brief overview of general information about this product. It does not include all information on possible applications, indications, warnings, precautions, interactions, adverse effects or risks that may be relevant to this product. This information is not specific medical advice and does not replace information obtained from your health care provider. You should check with your health care provider for complete information about the risks and benefits of using this product.